Companies › Newave Pharmaceutical
2 active drug programs in 5 registered trials: 4 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LP-118 selective treatment for hematological malignancies | – | Phase 1 | Non Hodgkin Lymphoma; Acute Leukemia; Philadelphia Positive Acute Lymphoblastic Leukemia | Dec 2026 |
| LP-168 Small molecule inhibitor | – | Phase 1 | CLL/SLL; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06207123 | LP-118 | Phase 1 | Acute Leukemia | Oncology | Dec 2026 |
| NCT04771572 | LP-118 | Phase 1 | Non Hodgkin Lymphoma | Oncology | Dec 2026 |
| NCT04775745 | LP-168 | Phase 1 | CLL/SLL | Oncology | Dec 2027 |
| NCT06978088 | LP-168 | Phase 2 | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Oncology | Jun 2029 |
| NCT07614022 | LP-118 | Phase 1 | Philadelphia Positive Acute Lymphoblastic Leukemia | Oncology | Mar 2030 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.